Phreesia, Inc. (NYSE:PHR) Given Average Rating of “Moderate Buy” by Brokerages

Phreesia, Inc. (NYSE:PHR) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $30.92.

A number of research firms have recently commented on PHR. Royal Bank of Canada reissued a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a research note on Thursday, March 21st. Stephens restated an “overweight” rating and issued a $28.00 price target on shares of Phreesia in a research note on Friday, May 31st. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Friday, May 31st. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday, May 31st. Finally, Raymond James restated an “outperform” rating and set a $30.00 target price (up previously from $25.00) on shares of Phreesia in a research note on Friday, March 15th.

Phreesia Trading Up 0.2 %

Shares of NYSE PHR opened at $21.20 on Friday. Phreesia has a 1 year low of $12.05 and a 1 year high of $34.98. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a 50-day moving average of $21.31 and a 200 day moving average of $23.18. The stock has a market cap of $1.22 billion, a P/E ratio of -9.77 and a beta of 0.92.

Phreesia (NYSE:PHR) last announced its earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.16. The business had revenue of $101.20 million during the quarter, compared to the consensus estimate of $100.94 million. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The business’s revenue for the quarter was up 20.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.70) earnings per share. As a group, sell-side analysts expect that Phreesia will post -1.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Evan Roberts sold 2,029 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $22.86, for a total value of $46,382.94. Following the transaction, the chief operating officer now directly owns 754,903 shares of the company’s stock, valued at approximately $17,257,082.58. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Phreesia news, COO Evan Roberts sold 2,029 shares of Phreesia stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $46,382.94. Following the transaction, the chief operating officer now owns 754,903 shares of the company’s stock, valued at $17,257,082.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Chaim Indig sold 12,043 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $22.62, for a total transaction of $272,412.66. Following the completion of the transaction, the chief executive officer now owns 1,225,397 shares of the company’s stock, valued at $27,718,480.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,359 shares of company stock worth $1,141,645. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Phreesia by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after purchasing an additional 194,035 shares during the period. Brown Advisory Inc. grew its stake in Phreesia by 22.2% during the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after acquiring an additional 716,374 shares in the last quarter. Capital International Investors increased its holdings in Phreesia by 221.1% in the 1st quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after acquiring an additional 1,785,463 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in Phreesia by 36.1% in the 3rd quarter. Rock Springs Capital Management LP now owns 1,776,391 shares of the company’s stock worth $33,183,000 after purchasing an additional 471,391 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Phreesia by 15.0% during the 4th quarter. Franklin Resources Inc. now owns 1,484,663 shares of the company’s stock valued at $34,370,000 after purchasing an additional 193,480 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.